ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is -28.18% lower on its value in year-to-date trading and has touched a low of $1.79 and a high of $5.70 in the current 52-week trading range. The ZIOP stock was last observed hovering at around $3.39 in the last trading session, with the day’s loss setting it -0.35% off its average median price target of $6.00 for the next 12 months. It is also 59.47% off the consensus price target high of $7.50 offered by 7 analysts, but current levels are -1.33% lower than the price target low of $3.00 for the same period.
Currently trading at $3.04, the stock is -5.71% and -6.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.93 million and changing -10.32% at the moment leaves the stock -14.75% off its SMA200. ZIOP registered -34.93% loss for a year compared to 6-month gain of 7.28%. The firm has a 50-day simple moving average (SMA 50) of $3.2703 and a 200-day simple moving average (SMA200) of $3.0520.
The stock witnessed a 3.99% loss in the last 1 month and extending the period to 3 months gives it a 13.38%, and is 6.27% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.24% over the week and 5.34% over the month.
Distance from 52-week low is 69.36% and -46.67% from its 52-week high.
ZIOPHARM Oncology Inc. (ZIOP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ZIOPHARM Oncology Inc. (ZIOP) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ZIOPHARM Oncology Inc. is expected to release its quarterly report on 11/09/2020 and quarterly earnings per share for the current quarter are estimated at -$0.09.The EPS is expected to shrink by -173.40% this year.
ZIOPHARM Oncology Inc. (ZIOP) Top Institutional Holders
199 institutions hold shares in ZIOPHARM Oncology Inc. (ZIOP), with 15.14M shares held by insiders accounting for 7.12% while institutional investors hold 51.76% of the company’s shares. The shares outstanding are 206.54M, and float is at 200.29M with Short Float at 16.20%. Institutions hold 48.07% of the Float.
ZIOPHARM Oncology Inc. (ZIOP) Insider Activity
A total of 0 insider transactions have happened at ZIOPHARM Oncology Inc. (ZIOP) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by MAUNEY DAVID M MD, the company’s President. SEC filings show that MAUNEY DAVID M MD sold 22,394 shares of the company’s common stock on Jan 02 at a price of $4.55 per share for a total of $0.1 million. Following the sale, the insider now owns 0.2 million shares.
ZIOPHARM Oncology Inc. disclosed in a document filed with the SEC on Jan 02 that Lafond Kevin G (SVP, Treasurer & CAO) sold a total of 21,570 shares of the company’s common stock. The trade occurred on Jan 02 and was made at $4.55 per share for $98144.0. Following the transaction, the insider now directly holds 63985.0 shares of the ZIOP stock.
Still, SEC filings show that on Jan 02, Hadfield Robert (General Counsel and Secretary) disposed off 16,853 shares at an average price of $4.55 for $76681.0. The insider now directly holds 100,719 shares of ZIOPHARM Oncology Inc. (ZIOP).
ZIOPHARM Oncology Inc. (ZIOP): Who are the competitors?
The company’s main competitors (and peers) include Cleveland BioLabs Inc. (CBLI) that is 89.44% higher over the past 12 months. Bristol-Myers Squibb Company (BMY) is 35.73% up on the 1-year trading charts. Short interest in the company’s stock has fallen 0.0% from the last report on Jun 29, 2020 to stand at a total of 32.13 million short shares sold with a short interest ratio of 21.63.